Tetracosactide

Tetracosactide, also known as cosyntropin or Synacthen, is a synthetic peptide that mimics the effects of adrenocorticotropic hormone (ACTH). It is a potent stimulator of the adrenal cortex, prompting the release of glucocorticoids, particularly cortisol, which plays a crucial role in regulating stress responses, immune function, and metabolic processes. Tetracosactide is primarily used in diagnostic tests for adrenal insufficiency, such as the ACTH stimulation test, and in certain cases, it may be used therapeutically to address adrenal insufficiency and related conditions.

Category

Synthetic ACTH analog

Sequence

H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH

Molecular Weight

Approximately 2933.5 g/mol

Molecular Formula

C136H210N40O31S

Half Life

Approximately 10–15 minutes

Most Common Uses

Tetracosactide is primarily used in medical settings to assess adrenal gland function. Physicians administer it as a diagnostic tool in the ACTH stimulation test to evaluate adrenal insufficiency, such as Addison’s disease or secondary adrenal failure, by measuring cortisol and aldosterone responses. The peptide is also employed therapeutically to manage certain inflammatory and autoimmune conditions, including multiple sclerosis flares, rheumatoid arthritis, and ulcerative colitis, due to its ability to stimulate cortisol production, which reduces inflammation.

In pediatric care, Tetracosactide is used to treat infantile spasms, a rare seizure disorder, helping to control symptoms and improve neurological outcomes. Typically administered via intramuscular or intravenous injection, its use is carefully monitored in clinical settings to ensure precise dosing and effective results. Ongoing research explores its potential in other endocrine and inflammatory disorders, though its applications remain limited by regulatory approvals in various regions.

Mechanism of Action

Tetracosactide stimulates the adrenal glands to produce and release cortisol and other corticosteroids. It binds to melanocortin-2 receptors (MC2R) on the surface of adrenal cortex cells, activating adenylate cyclase and increasing cyclic AMP levels, which triggers the synthesis and secretion of cortisol, aldosterone, and adrenal androgens. This process supports the body’s response to stress, regulates metabolism, and modulates inflammation. In diagnostic settings, Tetracosactide’s ability to rapidly elevate cortisol levels helps assess adrenal function, particularly in conditions like Addison’s disease.

Therapeutically, its stimulation of cortisol production reduces inflammation in autoimmune and inflammatory disorders, such as rheumatoid arthritis or multiple sclerosis flares. The peptide’s short half-life ensures quick onset and transient effects, making it suitable for controlled administration via intramuscular or intravenous injection in clinical settings.

Structure and Pharmacology

Tetracosactide is a synthetic peptide consisting of 24 amino acids, replicating the N-terminal sequence of adrenocorticotropic hormone (ACTH). Its sequence is H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH. The molecular formula is C136H210N40O31S, with a molecular weight of 2933.4 g/mol. This structure, featuring a methionine residue and multiple basic amino acids like lysine and arginine, ensures stability and effective binding to specific receptors. The design mimics natural ACTH, enabling Tetracosactide to stimulate adrenal gland activity while maintaining a predictable pharmacological profile.

Tetracosactide acts by binding to melanocortin-2 receptors (MC2R) on adrenal cortex cells, triggering the production and release of cortisol, aldosterone, and adrenal androgens. This binding activates adenylate cyclase, increasing cyclic AMP levels, which stimulates corticosteroid synthesis. The resulting cortisol elevation supports metabolic regulation, stress response, and inflammation suppression, making Tetracosactide valuable for both diagnostic and therapeutic purposes.

In diagnostic applications, such as the ACTH stimulation test, it rapidly increases cortisol levels to assess adrenal function in conditions like Addison’s disease. Therapeutically, it reduces inflammation in autoimmune disorders, such as rheumatoid arthritis or multiple sclerosis flares, and manages infantile spasms in pediatric patients. Tetracosactide has a short half-life of approximately 10–15 minutes, providing quick onset and transient effects. Its rapid clearance necessitates precise dosing schedules, tailored to individual patient needs under medical supervision, to optimize outcomes in clinical settings.

Dosages

Tetracosactide is administered via intramuscular or intravenous injection for diagnostic and therapeutic purposes in clinical settings. For diagnostic use a standard dose of 250 micrograms (mcg) is typically given as a single injection, with cortisol levels measured 30 to 60 minutes later to evaluate adrenal response. In therapeutic applications, such as managing infantile spasms or inflammatory conditions like multiple sclerosis flares or rheumatoid arthritis, doses vary based on patient needs. For adults, therapeutic doses typically range from 0.25-1 mg daily, administered intramuscularly, often for 3 to 5 days. In pediatric patients with infantile spasms, dosing is weight-based, commonly 20 to 40 mcg per kilogram per day, given intramuscularly over a 2- to 4-week course, with gradual tapering. The peptide is prepared by dissolving the lyophilized powder in sterile saline, ensuring proper administration. Dosing regimens are tailored to users’ conditions, with medical supervision guiding adjustments to achieve optimal outcomes.

Warnings and Cautions

Tetracosactide requires careful administration due to potential risks associated with its stimulation of corticosteroid production. Patients with known hypersensitivity to Tetracosactide or its components should avoid its use, as allergic reactions, including rash, swelling, or anaphylaxis, may occur and necessitate immediate medical attention. Those with conditions such as uncontrolled hypertension, heart failure, or Cushing’s syndrome need close monitoring, as increased cortisol levels may worsen these disorders. The peptide should not be used in patients with active infections, particularly fungal or viral, as corticosteroid elevation may suppress immune responses.

Pregnant or breastfeeding women should avoid using Tetracosactide, as safety data in these populations are limited. In pediatric patients, especially those treated for infantile spasms, long-term use may lead to growth suppression or adrenal axis dysregulation, requiring careful dose tapering. Common side effects include fluid retention, weight gain, or mood changes, and persistent symptoms warrant medical evaluation. Patients are monitored closely during treatment, with doses adjusted to minimize risks and ensure safe use in diagnostic or therapeutic applications.

Research & Clinical Trials

Safer Alternative for Postpartum Headaches

The study concluded that Tetracosactide, a man-made version of a natural hormone, could lower the need for an epidural blood patch in women who develop severe headaches after receiving anaesthesia during labour. Women treated with Tetracosactide were expected to have shorter-lasting headaches, less pain, fewer problems with daily activities, shorter hospital stays, and less need for extra treatments compared to those given a placebo. These results suggest that Tetracosactide may be a helpful and safer alternative to the standard blood patch procedure for treating this type of headache.

Protects the Spinal Cord from Ischemic Injury

The study showed that Tetracosactide can strongly protect the spinal cord from damage caused by a temporary loss of blood supply and the return of circulation in rabbits. Treatment with Tetracosactide lowered harmful stress and swelling in the tissue, increased the body’s natural defenses, reduced cell death, and improved both the structure of the spinal cord and overall movement function. Its effects were similar to those of methylprednisolone, the usual treatment, and in some cases, like reducing certain damaging enzymes, Tetracosactide worked even better. This is the first evidence that Tetracosactide can successfully protect the spinal cord from this type of injury, showing it could become a useful option for preventing spinal cord damage.

Tetracosactide and Anti-ACTH Antibody Responses

The study concluded that repeated administration of depot Tetracosactide (synthetic ACTH1–24) can trigger the production of antibodies against ACTH in patients, particularly those with autoimmune Addison’s disease. All patients who experienced adverse reactions after Tetracosactide injections had detectable anti-ACTH antibodies, and overall, 77% of trial participants developed these antibodies over time. The study also found that a significant number of patients with autoimmune Addison’s disease and Graves’ disease had spontaneous anti-ACTH reactivity even without Tetracosactide exposure. These antibodies may explain some of the adverse reactions to Tetracosactide and could contribute to resistance to chronic ACTH therapy.

Sourcing

USA

LIMITLESS LIFE NOOTROPICS aka Biotech

Use Discount Code: EP20

SCANTIFIX

Use Discount Code: Exploringpeptides

Canada

BIOSLAB

Use Discount Code: EP10

Europe

DNLABResearch

Use Discount Code: EP15

Australia

LVLUPHEALTH

References

[1] Depaulis, C., Steer, N., Garessus, L., Chassard, D., & Aubrun, F. (2020). Evaluation of the effectiveness and tolerance of tetracosactide in the treatment of post-dural puncture headaches (ESYBRECHE): a study protocol for a randomised controlled trial. Trials, 21(1), 55. https://doi.org/10.1186/s13063-019-4015-y

[2] Kertmen, H., Celikoglu, E., Ozturk, O. C., Gürer, B., Bozkurt, H., Kanat, M. A., Arikok, A. T., Erguder, B. I., Sargon, M. F., & Sekerci, Z. (2018). Comparative effects of methylprednisolone and tetracosactide (ACTH1-24) on ischemia/reperfusion injury of the rabbit spinal cord. Archives of medical science : AMS, 14(6), 1459–1470. https://doi.org/10.5114/aoms.2017.65650

[3] Gan, E. H., MacArthur, K., Mitchell, A. L., Joshi, A., Crock, P., & Pearce, S. H. S. (2015). Spontaneous and tetracosactide-induced anti-ACTH antibodies in man. Clinical Endocrinology, 83(6), 859–865. https://doi.org/10.1111/cen.12795

Related articles

SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

Adalank vs Selank: Differences, Benefits and Effects

Adamax vs Semax: Comparison, Benefits, and Effects

Common Mistakes When Reconstituting Peptides

Peptides Vs Proteins: What’s The Difference?

What Are Peptides and How Do They Work?